Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fondazione Italiana Sindromi Mielodisplastiche (FISiM) is a prominent Italian non-profit research foundation dedicated to advancing the study and treatment of myelodysplastic syndromes (MDS) and related hematological malignancies. The foundation coordinates a nationwide network of clinical centers, facilitating multicenter clinical trials and maintaining a comprehensive national patient registry to improve epidemiological understanding and clinical outcomes. FISiM's research focus includes the optimization of hypomethylating agents, the evaluation of novel targeted therapies, and the refinement of prognostic scoring systems. By bridging academic research with clinical practice, the foundation plays a pivotal role in establishing national diagnostic and therapeutic guidelines in Italy. Their work is essential for fostering innovation and improving the quality of life for patients suffering from myeloid neoplasms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fondazione Italiana Sindromi Mielodisplastiche.